AU2003286705A8 - Functional mri agents for cancer imaging - Google Patents

Functional mri agents for cancer imaging

Info

Publication number
AU2003286705A8
AU2003286705A8 AU2003286705A AU2003286705A AU2003286705A8 AU 2003286705 A8 AU2003286705 A8 AU 2003286705A8 AU 2003286705 A AU2003286705 A AU 2003286705A AU 2003286705 A AU2003286705 A AU 2003286705A AU 2003286705 A8 AU2003286705 A8 AU 2003286705A8
Authority
AU
Australia
Prior art keywords
functional mri
cancer imaging
mri agents
agents
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003286705A
Other versions
AU2003286705A1 (en
Inventor
Mattew J Allen
Douglas A Bakan
Thomas J Meade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Publication of AU2003286705A8 publication Critical patent/AU2003286705A8/en
Publication of AU2003286705A1 publication Critical patent/AU2003286705A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
AU2003286705A 2002-10-24 2003-10-24 Functional mri agents for cancer imaging Abandoned AU2003286705A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42147002P 2002-10-24 2002-10-24
US60/421,470 2002-10-24
PCT/US2003/034044 WO2004037210A2 (en) 2002-10-24 2003-10-24 Functional mri agents for cancer imaging

Publications (2)

Publication Number Publication Date
AU2003286705A8 true AU2003286705A8 (en) 2004-05-13
AU2003286705A1 AU2003286705A1 (en) 2004-05-13

Family

ID=34312085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286705A Abandoned AU2003286705A1 (en) 2002-10-24 2003-10-24 Functional mri agents for cancer imaging

Country Status (3)

Country Link
EP (1) EP1558137A2 (en)
AU (1) AU2003286705A1 (en)
WO (1) WO2004037210A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
EA201590622A1 (en) 2012-10-16 2015-10-30 Эндосайт, Инк. CONJUGATES FOR DELIVERY OF MEDICINES CONTAINING NOT MEETING IN THE NATURE OF AMINO ACID AND METHODS OF APPLICATION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives

Also Published As

Publication number Publication date
WO2004037210A3 (en) 2004-07-08
WO2004037210A2 (en) 2004-05-06
EP1558137A2 (en) 2005-08-03
AU2003286705A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU5753601A (en) Functional mri agents for cancer imaging
AU2002360766A8 (en) Methods for cancer imaging
EP1638612A4 (en) Cox-2-targeted imaging agents
GB2391707B (en) Imaging device
EP1535610A4 (en) Therapeutic agent for cancer
HK1089603A1 (en) Imaging device
IL175667A0 (en) Novel imaging agents
EP1679883A4 (en) Imaging apparatus
HK1087316A1 (en) Integrated multi-rail imaging system
EP1586941A4 (en) Imaging device
GB0318081D0 (en) Imaging system
EP1593999A4 (en) Imaging device
ZA200507598B (en) Imaging device
GB2393347B (en) Imaging device
HK1089602A1 (en) Imaging device
EP1619881A4 (en) Imaging device
GB0213031D0 (en) Imaging device
EP1670239A4 (en) Imaging device
AU2003213186A8 (en) Independent component imaging
GB0223162D0 (en) Imaging system
IL153183A0 (en) Agents for imaging and diagnostic methods using them
GB0301923D0 (en) Imaging system
EP1596601A4 (en) Imaging system
AU2003286705A8 (en) Functional mri agents for cancer imaging
GB0306678D0 (en) Imaging apparatus

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase